A Case of Anaplastic Thyroid Cancer that Became Resectable with Lenvatinib with Resultant Survival for Four Years
Author:
Affiliation:
1. Department of Endocrine and Breast Surgery, Osaka Police Hospital
2. Department of Diagnostic Pathology, Osaka Police Hospital
Publisher
Japan Surgical Association
Subject
General Engineering
Link
https://www.jstage.jst.go.jp/article/jjsa/81/12/81_2418/_pdf
Reference9 articles.
1. 1) Ark N, Zemo S, Nolen D, et al : Management of locally invasive well-differentiated thyroid cancer. Surg Oncol Clin N Am 2008 ; 17 : 145-155
2. 2) Haugen BR, Alexander EK, Bible KC, et al : American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer : The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016 ; 26 : 131-133
3. 3) Schlumberger M, Tahara M, Wirth L, et al : Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015 ; 372 : 621-630
4. 4) Cabanillas ME, Schlumberger M, Jarzab B, et al : A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer : A clinical outcomes and biomarker assessment. Cancer 2015 ; 121 : 2749-2756
5. 5) Tsuboi M, Takizawa H, Aoyama M, et al : Surgical treatment of locally advanced papillary thyroid carcinoma after response to lenvatinib : A case report. Int J Surg Case Rep 2017 ; 41 : 89-92
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3